We identified 1,116,805 statin and/or fibrate initiators who met eligibility criteria from January 1, 1998, through December 31, 2007. Of these, 86.6% were statin initiators, 12.9% were fibrate ...

A large cohort of patients who initiated statin or fibrate therapy was followed for the occurrence of new-onset rhabdomyolysis. Crude analyses indicated increased rhabdomyolysis risk on treatment ...

Several other studies have shown how fibrate therapy can potentially cause harm, like adverse kidney events and blood clots, or even liver injury and hospitalization when used concurrently with a ...

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration ...

SIADH (syndrome of inappropriate antidiuretic hormone secretion) leads to hyponatremia water retention in hospitalized or ...

Niacin (nicotinic acid) is used to prevent and treat niacin deficiency (pellagra). Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to ...

SIADH (syndrome of inappropriate antidiuretic hormone secretion) leads to hyponatremia water retention in hospitalized or ...